MX2022000426A - Telmisartan para el tratamiento de la hipertension en perros. - Google Patents

Telmisartan para el tratamiento de la hipertension en perros.

Info

Publication number
MX2022000426A
MX2022000426A MX2022000426A MX2022000426A MX2022000426A MX 2022000426 A MX2022000426 A MX 2022000426A MX 2022000426 A MX2022000426 A MX 2022000426A MX 2022000426 A MX2022000426 A MX 2022000426A MX 2022000426 A MX2022000426 A MX 2022000426A
Authority
MX
Mexico
Prior art keywords
telmisartan
treatment
dogs
hypertension
medicament
Prior art date
Application number
MX2022000426A
Other languages
English (en)
Inventor
Anne Michelle Traas
Amanda Erickson Coleman
De Moura Lourenco Bianca Natália Ferreira
Kate Elizabeth Creevy
Scott Alan Brown
Original Assignee
Boehringer Ingelheim Vetmedica Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Vetmedica Gmbh filed Critical Boehringer Ingelheim Vetmedica Gmbh
Publication of MX2022000426A publication Critical patent/MX2022000426A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a telmisartán o una de sus sales farmacéuticamente aceptables como un medicamento para el tratamiento de la hipertensión en perros, en donde la cantidad terapéuticamente efectiva de telmisartán se administra en una cantidad de dosis diaria que varía durante un período de tratamiento.
MX2022000426A 2019-07-09 2020-04-30 Telmisartan para el tratamiento de la hipertension en perros. MX2022000426A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962871749P 2019-07-09 2019-07-09
PCT/US2020/030581 WO2021006942A1 (en) 2019-07-09 2020-04-30 Telmisartan for the treatment of hypertension in dogs

Publications (1)

Publication Number Publication Date
MX2022000426A true MX2022000426A (es) 2022-04-25

Family

ID=70775532

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022000426A MX2022000426A (es) 2019-07-09 2020-04-30 Telmisartan para el tratamiento de la hipertension en perros.

Country Status (11)

Country Link
US (1) US20220226290A1 (es)
EP (1) EP3996709A1 (es)
JP (1) JP2022540077A (es)
KR (1) KR20220054292A (es)
CN (1) CN114173777A (es)
AU (1) AU2020310059A1 (es)
BR (1) BR112022000398A2 (es)
CA (1) CA3142877A1 (es)
MX (1) MX2022000426A (es)
TW (1) TW202116306A (es)
WO (1) WO2021006942A1 (es)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1908469A1 (en) * 2006-10-06 2008-04-09 Boehringer Ingelheim Vetmedica Gmbh Angiotensin II receptor antagonist for the treatment of systemic diseases in cats
CA3067918A1 (en) 2017-07-07 2019-01-10 Boehringer Ingelheim Vetmedica Gmbh Angiotensin ii receptor antagonish for the prevention or treatment of hypertension in cats

Also Published As

Publication number Publication date
WO2021006942A1 (en) 2021-01-14
US20220226290A1 (en) 2022-07-21
EP3996709A1 (en) 2022-05-18
CN114173777A (zh) 2022-03-11
JP2022540077A (ja) 2022-09-14
AU2020310059A1 (en) 2022-02-17
TW202116306A (zh) 2021-05-01
BR112022000398A2 (pt) 2022-03-03
KR20220054292A (ko) 2022-05-02
CA3142877A1 (en) 2021-01-14

Similar Documents

Publication Publication Date Title
NZ714963A (en) Compositions and methods for treating anemia
PH12015502691A1 (en) Use of high dose pridopidine for treating huntington's disease
MX2022003072A (es) Uso de pridopidina para el tratamiento de la disminucion funcional.
MX2024006689A (es) Sales monoacidas de 6-aminoisoquinolinas y usos de las mismas.
PH12018501001A1 (en) Therapeutic compositions for treatment of human immunodeficiency virus
MX2019012884A (es) Terapia de combinacion.
ZA202202361B (en) Treatment of hidradenitis suppurativa using jak inhibitors
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
MX2021002322A (es) Nuevos metodos.
MX2022015629A (es) Uso de vibegron para tratar vejiga sobreactiva.
ZA202006072B (en) Ret inhibitor for use in treating cancer having a ret alteration
NZ700924A (en) Dosage regimen for a pi-3 kinase inhibitor
PH12020551911A1 (en) Use of riluzole oral disintigrating tablets for treating diseases
MX2022000143A (es) Metodos novedosos.
EA201390618A1 (ru) Режимы дозирования при лечении офтальмологического сосудистого заболевания
MX2020013692A (es) Compuestos de pirazol e imidazol para la inhibicion de il-17 y rorgamma.
MX2022000426A (es) Telmisartan para el tratamiento de la hipertension en perros.
EP4299120A3 (en) Telmisartan for the prophylaxis or treatment of hypertension in cats
EA202193211A1 (ru) Лечение синуклеопатий
PH12016501026A1 (en) Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor
MX2022000429A (es) Telmisartan para el tratamiento de la enfermedad renal cronica en perros.
EA201590760A1 (ru) Применение бремеланотида в терапии женской сексуальной дисфункции
RU2011134582A (ru) Ингибирующее дипептидилпептидазу iv средство и фармацевтическая композиция на его основе
MX2022000373A (es) Combinacion de ibuprofeno y tramadol para aliviar el dolor.
EA202092944A1 (ru) Применение пероральных распадающихся таблеток рилузола для лечения заболеваний